

Publikationsliste Prof. Dr. med. Bertram Glaß

	Citation	IF
92	Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, Wulf G, Glass B , Pfreunds Schuh M, Einsele H, Arnold R, Stuhler G, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Wattad M, Hertenstein B, Klein S, Ringhoffer M, Mytilineos D, Tsamadou C, Mueller C, Schrezenmeier H, Mytilineos J. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. <i>Blood</i> . 2016 Dec 29;128(26):3169-3176. doi:10.1182/blood-2016-05-716357. Epub 2016 Nov 3. PubMed PMID: 27811019	11,847
91	Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B , Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N. Allogeneic Stem Cell Transplantation for Patients Age \geq 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biol Blood Marrow Transplant</i> . 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. PubMed PMID: 27720995.	3,980
90	Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Bouadballah R, Radford J, Bargetzi M, Ribrag V, Dührsen U, Ma D, Briere J, Thieblemont C, Bachy E, Moskowitz CH, Glass B , Gisselbrecht C. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplant</i> . 2016 Sep 19. doi: 10.1038/bmt.2016.213. [Epub ahead of print] PubMed PMID: 27643872.	3,636
89	3: Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B , Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler A. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>J Hematol Oncol</i> . 2016 Sep 17;9(1):89. doi: 10.1186/s13045-016-0321-y. PubMed PMID: 27639553; PubMed Central PMCID: PMC5027089.	6,263
88	Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B , Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreunds Schuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>J Clin Oncol</i> . 2016 Jul 5.pii: JCO656520. [Epub ahead of print] PubMed PMID: 27382100	20,982
87	Savani BN, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B , Socie' G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin NC, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A. Expanding transplant options to patients over 50 years- Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> . 2016 Mar 11. pii: haematol.2015.138180. [Epub ahead of print]	5,868
86	Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B , Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplant</i> . 2016 Jan;51(1):51-7.	3,570
85	Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TF, Bernd HW, Feller AC, Klapper W, Stuhlmann-Laeisz C, Hummel M, Stein H, Lenze D, Hartmann S, Hansmann ML, Möller P, Cogliatti S, Pfreunds Schuh M, Trümper L, Loeffler M, Glass B , Schmitz N, Ott G, Rosenwald A; DSHNHL16. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. <i>Leukemia</i> . 2015 Jul;29(7):1564-70	10,431
84	Schmitz N, Wu HS, Glass B . [Aggressive B-cell lymphoma: modern diagnostics and treatment]. <i>Dtsch Med Wochenschr</i> . 2014 Oct;139(41):2082-5.	0,550
83	Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hänel M, Witzens-Harig M, Mahlberg R, Rube C, Fleckenstein J, Zwick C, Glass B , Schmitz N, Zeynalova S, Pfreunds Schuh M. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. <i>Blood</i> . 2014 Jul 31;124(5):720-8.	10,452
82	Glass B , Hasenkamp J, Wulf G, Dreger P, Pfreunds Schuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer P, Hilgers R, Truemper L, Schmitz N, on behalf of the German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial Original Research Article. <i>The Lancet Oncology</i> , In Press, Corrected Proof, Available online 11 May 2014	25,117

81	Schmitz N, Wu HS, Glass B . Allogeneic transplantation in T-cell lymphomas. <i>Semin Hematol</i> . 2014 Jan;51(1):67-72. doi: 0.1053 / j.seminhematol. 2013.11.010. Epub 2013 Nov 28. Review.	3,357
80	Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rube C, Zwick C, Glass B , Schmitz N, Pfreundschuh M. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. <i>J Clin Oncol</i> . 2013 Nov 10;31(32):4115-22. doi: 10.1200/JCO.2012.48.0467. Epub 2013 Sep 23.	18,038
79	Fürst D, Müller C, Vucinic V, Bunjes D, Herr W, Gramatzki M, Schwerdtfeger R, Arnold R, Einsele H, Wulf G, Pfreundschuh M, Glass B , Schrezenmeier H, Schwarz K, Mytilineos J. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. <i>Blood</i> . 2013 Oct 31;122(18):3220-9. doi: 10.1182/blood-2013-02-482547.	9,063
78	Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B . Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). <i>Lancet Oncol</i> 2012;(12):10-2045.	22,589
77	Gisselbrecht C, Schmitz N, Mounier N, Singh GD, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Duhrsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Briere J, Salles G, Moskowitz CH, Glass B . Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>J Clin Oncol</i> 2012.	18,970
76	Schmitz N, Nickelsen M, Glass B . Autologous or allogeneic transplantation in B- and T-cell lymphomas. <i>Best Practice & Research Clinical Haematology</i> 2012;25(1): 61-73.	2,637
75	Schmitz N, Zeynalova S, Glass B , Kaiser U, Cavallin-Stahl E, Wolf M, Haenel M, Loeffler M, Truemper L, Pfreundschuh M. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Annals of Oncology</i> 2012;23(5): 1267-73.	6,452
74	Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glass B , Hasenkamp J, Meller J, Riggert J, Truemper L, Griesinger F. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue. <i>Annals of Hematology</i> 2011;90(11):1307-15.	2,688
73	Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. <i>Blood</i> 2011;117(5):1516-21.	10,558
72	Borgerding A, Hasenkamp J, Glass B , Wulf G, Truemper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. <i>Annals of Hematology</i> 2010;89(3):283-9.	2,688
71	Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Truemper L, Wienands J, Glass B . B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. <i>Experimental Hematology</i> 2010;38(3):213-21.	3,198
70	Gisselbrecht C, Glass B , Mounier N, Gill DS, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> 2010;28(27):4184-90.	21,136
69	Glass B . Prophylaxis of fungal infections in haematological patients: pro. <i>Deutsche Medizinische Wochenschrift</i> 2010;135(38):1870.	0,500
68	Glass B , Ziepert M, Reiser M, Freund M, Truemper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> 2010;21(11):2255-61.	6,452
67	Hasenkamp J, Borgerding A, Wulf G, Schmitz N, Truemper L, Glass B . Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells. <i>Annals of Hematology</i> 2010;89(4):341-8.	2,688
66	Ziepert M, Hasenclever D, Kuhnt E, Glass B , Schmitz N, Pfreundschuh M, Loeffler M. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20(+) B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> 2010;28(14):2373-80.	18,970
65	Nickelsen M, Ziepert M, Zeynalova S, Glass B , Metzner B, Leithaeuser M, Mueller-Hermelink H, Pfreundschuh M, Schmitz N. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). <i>Annals of Oncology</i> 2009;20(12):1977-84.	6,458

64	Basecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B , Schmitz N, Trumper L, Griesinger F. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. <i>British Journal of Haematology</i> 2008;141(1):52-9.	4,942
63	Gleissner B, Kueppers R, Siebert R, Glass B , Truemper L, Hiddemann W, Dreyling M. Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. <i>British Journal of Haematology</i> 2008;142(2):166-78.	4,942
62	Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, Jung W, Truemper L, Glass B . Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors. <i>Scandinavian Journal of Immunology</i> 2008;67(3):218-29.	1,935
61	Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Truemper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B , Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). <i>Lancet Oncology</i> 2008;9(2):105-16.	17,764
60	Gisselbrecht C, Bethge W, Duarte R, Gianni A, Glass B , Haioun C, Martinelli G, Nagler A, Pettengell R, Sureda A, Tilly H, Wilson K. Current status and future perspectives for yttrium-90 (Y-90)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> 2007;40(11):1007-17.	3,660
59	Schmitz N, Dreger P, Glass B , Sureda A. Allogeneic transplantation in lymphoma: current status. <i>Haematologica-the Hematology Journal</i> 2007;92(11):1533-48.	6,532
58	Basecke J, Karim K, Podleschny M, Becker A, Glass B , Trumper L, Griesinger F. MLL rearrangements emerge during spontaneous apoptosis of clinical blood samples. <i>Leukemia</i> 2006; 20(6):1193-1194.	6,612
57	Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O, Sandrock D, Munz DL, Glass B , Thiel E, Blau IW. Allogeneic hematopoietic cell transplantation following conditioning with Y-90-ibritumomab-tiuxetan. <i>Leukemia & Lymphoma</i> 2006; 47(1):59-63.	1,295
56	Glass B , Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, Trumper L, Loeffler M, Pfreundschuh M, Schmitz N. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. <i>Blood</i> 2006; 107(8):3058-3064.	10,131
55	Hasenkamp J, Borgerding A, Wulf G, Uhrberg M, Jung W, Dingeldein S, Truemper L, Glass B . Resistance against natural killer cell cytotoxicity: Analysis of mechanisms. <i>Scandinavian Journal of Immunology</i> 2006; 64(4):444-449.	2,023
54	Schiel X, Link H, Maschmeyer G, Glass B , Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Osterman H, Hentrich M. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. <i>Infection</i> 2006; 34(3):118-126.	1,854
53	Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B . Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation - Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. <i>Cancer</i> 2006; 106(1):136-145.	4,800
52	Wulf GG, Boehnke A, Chapuy B, Glass B , Hemmerlein B, Schroers R, Brenner MK, Truemper L. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. <i>Haematologica-the Hematology Journal</i> 2006; 91(7):886-894.	4,575
51	Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B . Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> 2005; 36(3):271-273.	2,643
50	Wulf GG, Sadowski B, von Bonin F, Glass B , Truemper L. Bone marrow side population (SP) cells are donor derived after allogeneic stem cell transplantation in humans. <i>Bone Marrow Transplantation</i> 2005; 36(2):179-180.	2,643
49	Glass B , Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G, Trumper L, Schmitz N. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. <i>Bone Marrow Transplant</i> 2004; 34(5):391-397.	2,643

48	Pfreunds Schuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B , Rube C, Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i> 2004; 104(3):626-633.	10,131
47	Schanz J, Wolf C, Koehler M, Maas JH, Meyer M, Neumeyer H, Legler TJ, Wulf G, Glass B , Truemper L, Riggert J. Rhabdomyolysis in allogeneic peripheral blood stem cell donors. <i>Vox Sanguinis</i> 2004; 86(4):263-265.	1,888
46	Schroers R, Hildebrandt Y, Hasenkamp J, Glass B , Lieber A, Wulf G, Piesche M. Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. <i>Experimental Hematology</i> 2004; 32(6):536-546.	4,019
45	Trumper L, Glass B , Hartmann F, Pfreunds Schuh M. [New diagnostic and therapeutic strategies for aggressive lymphomas]. <i>Dtsch Med Wochenschr</i> 2004; 129(40):2113-2117.	0,653
44	Wulf GG, Viereck V, Hemmerlein B, Haase D, Vehmeyer K, Pukrop T, Glass B , Emons G, Trumper L. Mesengenic progenitor cells derived from human placenta. <i>Tissue Eng</i> 2004; 10(7-8):1136-1147.	2,887
43	Hartung G, Zeis M, Glass B , Dreger P, Steinmann J, Schmitz N, Uharek L. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model. <i>Bone Marrow Transplantation</i> 2003; 32(1):49-56.	2,643
42	Claviez A, Glass B , Dreger P, Suttorp M. Elevated blood drug levels obtained from indwelling silicon catheters during oral cyclosporine A administration. <i>Bone Marrow Transplant</i> 2002; 29(6):535-536.	2,643
41	Schmits R, Glass B , Trumper L, Pfreunds Schuh M. Therapeutic strategies for aggressive lymphomas: The trials of the DSHNHL. <i>Annals of Hematology</i> 2001; 80:B77-B83.	2,193
40	Seyfarth B, Kuse R, Sonnen R, Glass B , Schmitz N, Dreger P. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? <i>Annals of Hematology</i> 2001; 80(7):398-405.	2,193
39	Zeis M, Uharek L, Hartung G, Glass B , Steinmann J, Schmitz N. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice. <i>Hematol J</i> 2001; 2(2):136-144.	4,575
38	Dreger P, Viehmann K, von Neuhoff N, Kruss D, Glass B , Kneba M, Mitsky P, Jopp P, Rautenberg P, Mills B, Schmitz N. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. <i>Experimental Hematology</i> 2000; 28(10):1187-1196.	4,019
37	Dreger P, Glass B , Seyfarth B, Humpe A, Claviez A, von Neuhoff N, Suttorp M, Schoch R, Schmitz N. Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT. <i>Bone Marrow Transplant</i> 2000; 26(12):1361-1362.	2,643
36	Dreger P, Martin S, Kuse R, Sonnen R, Glass B , Kroger N, Parwaresch R, Kneba M, Schmitz N, Haas R. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. <i>Hematol J</i> 2000; 1(2):87-94.	4,575
35	Dreger P, Glass B , Kuse R, Sonnen R, von Neuhoff N, Bolouri H, Kneba M, Schmitz N. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. <i>British Journal of Haematology</i> 1999; 106(1):115-118.	4,080
34	Dreger P, Viehmann K, von Neuhoff N, Glaubitz T, Petzoldt O, Glass B , Uharek L, Rautenberg P, Suttorp M, Mills B, Mitsky P, Schmitz N. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. <i>Bone Marrow Transplantation</i> 1999; 24(2):153-161.	2,643
33	Fandrich F, Schlemminger M, Glass B , Suttorp M, Henne-Bruns D, Kremer B. Specific tolerance induction after recipient conditioning with donor stem cells: A relevant clinical model of living-organ donation for solid organs. <i>Langenbecks Archives of Surgery</i> 1999; 739-744.	1,367
32	Lehmann C, Glass B , Zeis M, Schmitz N, Uharek L. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity. <i>Cancer Immunol Immunother</i> 1999; 48(4):209-213.	4,086

31	Maschmeyer G, Hertenstein B, Glass B, Schiel X. [Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology]. Deutsche medizinische Wochenschrift (1946) 1999;124 Suppl 1:S9-13.	0,406
30	Dreger P, von Neuhoff N, Kuse R, Sonnen R, Glass B, Uharek L, Schoch R, Loffler H, Schmitz N, Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? British Journal of Cancer 1998;77(12):2291-7,	4,936
29	Glass B, Uharek L, Hartung G, Zeis M, Steinmann J, Dreger P, Kronke M, Schmitz N, Immunotherapeutic aspects of allogeneic peripheral progenitor cells, Bone Marrow Transplantation 1998;21:S3-S8,	3,339
28	Hartung G, Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Kronke M, Schmitz N. Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. Bone Marrow Transplantation 1998;21:S16-S20.	3,339
27	Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Loffler H, Schmitz N. Abrogation of graft-vs.-leukemia activity after depletion of CD3(+) T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). Experimental Hematology 1998;26(2):93-9.	3,290
26	Zeis M, Uharek L, Glass B, Vosskotter W, Dreger P, Schmitz N, Steinmann J. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Experimental Hematology 1998;26(11):1068-73.	3,290
25	Dreger P, Glass B, Uharek L, Zeis M, Schmitz N. Allogenic transplantation of mobilized peripheral blood progenitor cells: Towards tailored cell therapy. International Journal of Hematology 1997;66(1):1-11.	1,325
24	Dreger P, vonNeuhoff N, Kuse R, Sonnen R, Glass B, Uharek L, Bartels H, Loffler H, Schmitz N. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Annals of Oncology 1997;8(4):401-3.	5,660
23	Glass B, Uharek L, Zeis M, Dreger P, Loffler H, Steinmann J, Schmitz N. Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 1997;90(4):1694-700.	10,075
22	Glass B, Majolino I, Dreger P, Scime R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation. Bone Marrow Transplantation 1997;20(7):533-41.	3,339
21	Maschmeyer G, Hiddemann W, Link H, Cornely OA, Buchheidt D, Glass B, Adam D. Management of infections during intensive treatment of hematologic malignancies. Annals of Hematology 1997;75(1-2):9-16.	2,471
20	Zeis M, Uharek L, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. British Journal of Haematology 1997;96(4):757-61.	4,565
19	Dreger P, Glass B, Uharek L, Schmitz N. Allogeneic peripheral blood progenitor cells: current status and future directions. Journal of hematotherapy 1996;5(4):331-713	0,000
18	Glass B, Uharek L, Zeis M, Loeffler H, MuellerRuchholtz W, Gassmann W. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia. British Journal of Haematology 1996;93(2):412-20.	4,565
17	Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N, MullerRuchholtz W. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia 1996;10(11):1758-64.	7,761
16	Salomo M, Steinmann J, Glass B, Herwartz C, Uharek L, Gassmann W, MullerRuchholtz W. Leukemia-Specific Allogeneic Donor T-Cells - Quantification by Limiting Dilution Assay. Bone Marrow Transplantation 1995;15(2):179-86.	3,339
15	Sebens T, Uharek L, Glass B, MullerRuchholtz W, Steinmann J. Allogeneic Mouse T-Cell Lines Distinguish 3 Balb/C Leukemias from Each Other and from Nonleukemic Lymphocytes. Bone Marrow Transplantation 1995;16(3):443-9.	3,339
14	Steinmann J, Glass B, Herwartz C, Salomo M, Sebens T, Uharek L, MullerRuchholtz W. In-Vitro Generation of Allogeneic Rather Than Syngeneic Cytotoxic T-Cells for Leukemia Therapy. Transplantation Proceedings 1995;27(1):637-9.	1,046
13	Zeis M, Uharek L, Glass B, Gaska T, Steinmann J, Gassmann W, Loffler H, MullerRuchholtz W. Allogeneic Nk Cells As Potent Antileukemic Effector-Cells After Allogeneic Bone-Marrow Transplantation in Mice. Transplantation 1995;59(12):1734-6.	3,660

12	Uharek L, Glass B, Gaska T, Gassmann W, Loeffler H, MuellerRuchholtz W. Influence of Donor Lymphocytes on the Incidence of Primary Graft Failure After Allogeneic Bone-Marrow Transplantation in A Murine Model. British Journal of Haematology 1994;88(1):79-87.	4,565
11	Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, MuellerRuchholtz W. Induction of Graft-Versus-Leukemia (Gvl) Activity in Murine Leukemia Models After Il-2 Pretreatment of Syngeneic and Allogeneic Bone-Marrow Grafts. Bone Marrow Transplantation 1994;14(5):711-5.	3,339
10	Glass B, Uharek L, Gaska T, Gassmann W, Loeffler H, MullerRuchholtz W. The Influence of Graft-Versus-Host Reactivity, Lymphocyte Depletion, and Cell Dose on Allogeneic Bone-Marrow Engraftment. Bone Marrow Transplantation 1993;12:S41-S47.	3,339
9	Haferlach T, Loeffler H, Glass B, Gassmann W. Repeated Complete Remission in A Patient with Acute Promyelocytic Leukemia After Treatment with 13-Cis-Retinoic Acid 1St and with All-Trans-Retinoic Acid in Relapse. Clinical Investigator 1993;71(10):774-91	0,000
8	Schmitz N, Glass B, Dreger P, Haferlach T, Horst HA, Ollechchwoyka J, Suttorp M, Gassmann W, Loeffler H. High-Dose Chemotherapy and Hematopoietic Stem-Cell Rescue in Patients with Relapsed Hodgkins-Disease. Annals of Hematology 1993;66(5):251-6.	2,471
7	Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Loeffler H, MullerRuchholtz W. Natural-Killer-Cells As Effector-Cells of Graft-Versus-Leukemia Activity in A Murine Transplantation Model. Bone Marrow Transplantation 1993;12:S57-S60.	3,339
6	Glass B, Uharek L, Gassmann W, Focks B, Bolouri H, Loeffler H, MuellerRuchholtz W. Graft-Versus-Leukemia Activity After Bone-Marrow Transplantation Does Not Require Graft-Versus-Host Disease. Annals of Hematology 1992;64(6):255-9.	2,471
5	Luszyk D, Eggert F, Uharek L, Glass B, MullerRuchholtz W, Ferstl R. Characteristics of Olfactory Response Modification After Experimental Bone-Marrow Transplantation. Zeitschrift fur Experimentelle und Angewandte Psychologie 1992;39(2):249-62.	0,000
4	Uharek L, Glass B, Gassmann W, Eckstein V, Steinmann J, Loeffler H, MuellerRuchholtz W. Engraftment of Allogeneic Bone-Marrow Cells - Experimental Investigations on the Role of Cell Dose, Graft-Versus-Host Reactive T-Cells and Pretransplant Immunosuppression. Transplantation Proceedings 1992;24(6):3023-5.	1,046
3	Uharek L, Gassmann W, Glass B, Steinmann J, Loeffler H, MuellerRuchholtz W. Influence of Cell Dose and Graft-Versus-Host Reactivity on Rejection Rates After Allogeneic Bone-Marrow Transplantation. Blood 1992;79(6):1612-21.	10,075
2	Gassmann W, Uharek L, Erbersdobler A, Glass B, Wottge HU, Schmitz N, Loeffler H, MuellerRuchholtz W. High-Dose Cytostatic Agents in Allogeneic Bone-Marrow Transplantation - Comparison of the Engraftment Promoting Potential. British Journal of Haematology 1991;78(3):310-8.	4,566
1	Gassmann W, Erbersdobler A, Uharek L, Glass B, Loeffler H, MuellerRuchholtz W. Ifosfamide and Acnu in Experimental Allogeneic Bone-Marrow Transplantation. Journal of Cancer Research and Clinical Oncology 1991;117:S224-S227.	2,423

Stand September 2017